| COX-2 |  |
Cyclooxygenase-2 catalyzes the conversion of arachidonic acid to prostaglandin H2 in the first step in the biosynthesis of prostaglandins, thromboxanes, and prostacyclins. COX-2 inhibition by nonsteroidal antiinflamatory agents has been shown to decrease angiogenesis, and tumor growth, and promote apoptosis. COX-2 overexpression has been associated with increased microvascular density, and VEGF protein expression in head and neck squamous cell carcinoma and is a poor prognostic indicator in this entity as well. COX-2 overexpression has also been suggested as a poor prognostic indicator in carcinomas of the colon, breast, pancreas, and adenocarcinoma of the lung.
Rabbit Monoclonal, Clone: SP21
|
Regulatory Status
|
 |
||||||||||||||||||||||||||||||||||
